In Regard to Redmond et al

To the Editor: With interest we read the article by Redmond et al (1) reporting on a prospective study of hippocampal-sparing prophylactic cranial irradiation (HS-PCI) in limited stage small cell lung cancer (SCLC). Within this trial, 20 patients with limited-stage SCLC showing a complete response to chemoradiation therapy and no brain metastases received HS-PCI up to 25 Gy in 10 fractions. At baseline and at 6 and 12 months, magnetic resonance imaging and a battery of neuropsychological tests were performed.

http://ift.tt/2vcKAh3